Disc Medicine Inc. (IRON) is a Healthcare · Biotechnology company listed on NASDAQ. Price $68.49 (-1.00%), Market cap $2.55B, 52-week low–high $45.12 ~ $94.11.
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the
Financial statements, price targets, institutional (13F) holdings and related news for Disc Medicine Inc. are updated in real time on BlackAll Trade.
Disc Medicine Inc. trades at $68.49 (-1.00%). Real-time quotes and charts are available on BlackAll Trade.
Disc Medicine Inc. has a market cap of about $2.55B.
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering